Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Change in Accured Expenses (2019 - 2025)

Historic Change in Accured Expenses for Cyclerion Therapeutics (CYCN) over the last 7 years, with Q3 2025 value amounting to $85000.0.

  • Cyclerion Therapeutics' Change in Accured Expenses rose 14047.62% to $85000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $27000.0, marking a year-over-year increase of 10321.05%. This contributed to the annual value of -$515000.0 for FY2024, which is 6748.74% up from last year.
  • Per Cyclerion Therapeutics' latest filing, its Change in Accured Expenses stood at $85000.0 for Q3 2025, which was up 14047.62% from -$138000.0 recorded in Q2 2025.
  • In the past 5 years, Cyclerion Therapeutics' Change in Accured Expenses ranged from a high of $462000.0 in Q2 2023 and a low of -$3.4 million during Q1 2021
  • Moreover, its 5-year median value for Change in Accured Expenses was -$186000.0 (2022), whereas its average is -$362526.3.
  • Within the past 5 years, the most significant YoY rise in Cyclerion Therapeutics' Change in Accured Expenses was 52777.78% (2023), while the steepest drop was 63636.36% (2023).
  • Over the past 5 years, Cyclerion Therapeutics' Change in Accured Expenses (Quarter) stood at -$281000.0 in 2021, then soared by 33.81% to -$186000.0 in 2022, then plummeted by 97.31% to -$367000.0 in 2023, then skyrocketed by 88.83% to -$41000.0 in 2024, then soared by 307.32% to $85000.0 in 2025.
  • Its last three reported values are $85000.0 in Q3 2025, -$138000.0 for Q2 2025, and $121000.0 during Q1 2025.